Mr. Speaker, I am pleased to rise today to express our government's support for Bill S-201, which seeks to establish a national framework to support Canadians with sickle cell disease. I want to express my sincere thanks to Senator Ince and Senator Mégie for their hard work in the Senate and for their advocacy. I want to also thank my dear friend, the hon. member for Scarborough—Woburn, for all his work in the House of Commons and his years of advocacy on this issue.
This is an important bill. It passed the Senate with unanimous support, and I hope we will do the same here in the House. Bill S-201 asks us to consider how a national framework could improve consistency, coordination and outcomes for Canadians living with sickle cell disease. The bill invites us to consider not only the individuals directly affected but also the families, caregivers and communities that share the burden of managing this complex condition.
I think it is important to talk about what sickle cell disease is, because it is not well-known, as the member mentioned. As with any rare disease, raising awareness is a key step in building broader understanding.
Sickle cell disease is a group of inherited blood disorders where red blood cells form an abnormal sickle shape. This can lead to reduced life expectancy and acute episodes of severe pain, commonly referred to as sickle cell crises. Current treatments include blood transfusions and medications aimed at reducing the frequency of pain crises. Stem cell transplants offer a potential cure but are limited by donor availability and significant medical risk. Emerging gene therapies show promise but come with extremely high costs.
Approximately 6,000 Canadians live with this condition, and there is a disproportionate impact on people of African, Caribbean, Middle Eastern and South Asian ancestry. Black Canadians in particular bear the brunt of sickle cell disease. Approximately one in 10 black Canadians carry the sickle cell gene mutation, yet because the disease is so poorly known and understood, Black patients frequently report discrimination in care, which leads to delayed diagnosis, increased reliance on emergency services and poor health outcomes. Limited clinical expertise, inconsistent guidelines and under-representation of Black health professionals further compound these challenges.
There has been some progress toward national training standards. Canadian Blood Services formally endorsed the sickle cell disease education program for health care professionals, a program developed by the Sickle Cell Awareness Group of Ontario. This represents a credible evidence-based framework already available to jurisdictions across the country. Established standards such as these could ensure greater consistency in care and strengthen our collective capacity to support Canadians living with sickle cell disease.
We also know that research can play an enormous role in furthering our understanding of this disease. That is why it is so exciting to hear that the Canadian Institutes of Health Research has supported significant research efforts in this field, including an investment of $13.8 million in new sickle cell-related research over the past decade. This represents a strong foundation on which to build that will create opportunities for Canadian researchers to continue advancing knowledge, improve diagnosis and treatment, and ultimately enhance the quality of life for individuals and the families affected by sickle cell disease.
Standardized care pathways are also important. We have started to see progress on this front as well. For example, the Canadian Hemoglobinopathy Association developed and published comprehensive clinical guidelines that outline best practices for both diagnosis and treatment.
I am pleased to report that Ontario has already integrated these guidelines into the Ontario health quality standard related to sickle cell disease. Hopefully more provinces and territories will follow its lead. Similarly, several provinces and territories have already established standards related to newborn screening notification, diagnostic processes and ongoing care for individuals living with sickle cell disease that integrate these national standards. These efforts demonstrate the important progress that is being made at the regional level.
The federal government has a role to play here as well, and we have been. Thanks to funding under the national strategy for drugs for rare diseases, Canada's Drug Agency is supporting greater consistency in newborn screening across the country, including a recommended pan-Canadian list of conditions to screen for newborns that is inclusive of sickle cell disease. Thanks to this approach at a national level, 11 provinces and territories now screen newborns for sickle cell disease, and this condition is under review or development in the remaining jurisdictions.
In fighting against sickle cell disease, however, nothing is more important than education, and Bill S-201 recognizes this. We need to raise public awareness of sickle cell disease, especially the critical importance of blood donation.
In 2017, the House unanimously adopted Bill S-211, which created National Sickle Cell Awareness Day on June 19. Thanks to this bill, which was sponsored by my colleague, the member for Dartmouth—Cole Harbour, there is a national spotlight on the experiences of individuals and families affected by sickle cell disease.
We also have Sickle Cell Awareness Month every September, during which Canadian Blood Services, the provinces and territories collaborate, increasing the understanding of the disease and encouraging blood donation, with a particular focus on engaging donors from African, Caribbean and Black communities. These efforts are critical because donation rates among under-represented communities remain low. Less than 1% of Canada's blood donor base is from Black individuals, despite the disproportionate impact of sickle cell disease among this population. By increasing awareness of the disease and of what we can do to treat it, we can work to meet the transfusion needs of many patients living with sickle cell disease.
Bill S-201 presents a framework that aims to address many of the challenges faced by Canadians living with sickle cell disease. The principles associated with each of the bill's nine elements underscore both the importance of the issue and the complexity of the solutions. I look forward to continuing the discussion and to hearing the perspective of all members of this House. I hope all of us will join together to pass this important bill.
